Form 10-Q Imprimis Pharmaceuticals For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Imprimis Pharma (IMMY) Reports Q3 Loss of $0.29/Share
November 14, 2016 5:20 PM ESTImprimis Pharma (NASDAQ: IMMY) reported Q3 EPS of ($0.29), versus ($0.41) reported last year. Revenue for the quarter came in at $4.9 million, versus $2.7 million reported last year.
For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.
... More